HC Wainwright Analysts Lift Earnings Estimates for GALT

Galectin Therapeutics Inc. (NASDAQ:GALT) – Equities researchers at HC Wainwright lifted their Q3 2026 EPS estimates for Galectin Therapeutics in a note issued to investors on Friday, August 14th. HC Wainwright analyst M. Keller now expects that the company will post earnings per share of ($0.05) for the quarter, up from their previous forecast of ($0.10). HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Galectin Therapeutics’ current full-year earnings is ($0.37) per share. HC Wainwright also issued estimates for Galectin Therapeutics’ Q4 2026 earnings at ($0.05) EPS, FY2026 earnings at ($0.30) EPS and FY2027 earnings at ($0.23) EPS.

Galectin Therapeutics (NASDAQ:GALT) last released its earnings results on Friday, August 14th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.05).

A number of other brokerages have also recently commented on GALT. Weiss Ratings raised Galectin Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 18th. Wall Street Zen upgraded Galectin Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, June 13th. Finally, Zacks Research upgraded shares of Galectin Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 11th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $11.00.

Galectin Therapeutics Trading Up 2.0%

Shares of Galectin Therapeutics stock opened at $3.51 on Tuesday. Galectin Therapeutics has a twelve month low of $2.03 and a twelve month high of $7.13. The firm has a market capitalization of $231.17 million, a PE ratio of -8.16 and a beta of 0.41. The firm’s 50-day moving average price is $3.63 and its 200 day moving average price is $3.00.

Hedge Funds Weigh In On Galectin Therapeutics

A number of hedge funds have recently modified their holdings of GALT. Jane Street Group LLC acquired a new stake in Galectin Therapeutics during the 2nd quarter worth $1,580,000. Goldman Sachs Group Inc. raised its holdings in shares of Galectin Therapeutics by 1,295.6% in the fourth quarter. Goldman Sachs Group Inc. now owns 307,229 shares of the company’s stock valued at $1,278,000 after buying an additional 285,215 shares during the last quarter. 683 Capital Management LLC acquired a new stake in shares of Galectin Therapeutics during the fourth quarter worth about $676,000. Renaissance Technologies LLC acquired a new stake in shares of Galectin Therapeutics during the first quarter worth about $413,000. Finally, Wellington Management Group LLP acquired a new position in Galectin Therapeutics in the 4th quarter valued at about $592,000. 11.68% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Galectin Therapeutics

In related news, Director Harold H. Shlevin sold 22,268 shares of the business’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $5.04, for a total value of $112,230.72. Following the completion of the sale, the director directly owned 6,500 shares of the company’s stock, valued at $32,760. The trade was a 77.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Khurram Jamil sold 47,467 shares of Galectin Therapeutics stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $5.04, for a total value of $239,233.68. Following the transaction, the insider directly owned 2,037 shares in the company, valued at approximately $10,266.48. This trade represents a 95.89% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 90,162 shares of company stock valued at $438,464 in the last three months. 52.60% of the stock is currently owned by insiders.

About Galectin Therapeutics

Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company’s lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.

Founded in 2000, the company is headquartered in Norcross, Georgia, where it oversees discovery research, preclinical studies and clinical trial coordination.